Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Repligen Corporation has approached Maravai Lifesciences Holdings Inc. with an acquisition offer, according to sources. The report led to a significant increase in Maravai's share price, which was halted after rising by 11%. However, there is no certainty that Maravai will agree to the deal. Repligen is also considering whether to divest some of Maravai's divisions if the acquisition is successful.
Polen Capital on Construction Partners $ROAD US Thesis: Construction Partners stands out with its focus on recurring, low-risk maintenance work, ensuring stable growth and robust margins (Extract from their Q2 letter) https://t.co/6Ag1cmLjcZ
Polen Capital on Repligen $RGEN US Thesis: Repligen is primed to capitalize on its technical leadership in bioprocessing as the industry recovers from pandemic disruptions (Extract from their Q2 letter) https://t.co/uw8uBBH7G5
"There is no certainty that Maravai will agree to a deal and Repligen is also deliberating whether it should divest some of Maravai's divisions if it succeeds in acquiring the company, sources told Reuters." $MRVI
